Positive Airway Pressure Therapy Predicts Lower Mortality and Major Adverse Cardiovascular Events Incidence in Medicare Beneficiaries with Obstructive Sleep Apnoea


1Division of Medical Informatics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
2Division of Medical Informatics, Department of Pulmonary, Critical Care and Sleep Medicine, University of Kansas Medical Center, Kansas City, KS, USA
3Department of Health Management and Informatics, School of Medicine, University of Missouri-Columbia, MO, USA
4College of Nursing, University of Nebraska Medical Center, Omaha, NE, USA
5Department Division of Pulmonary and Critical Care Medicine, Department of Medicine University of Utah, Salt Lake City, UT, USA
6Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA

*Corresponding author
Diego R. Mazzotti, Ph.D.
Division of Medical Informatics, Department of Internal Medicine
University of Kansas Medical Center
3901 Rainbow Boulevard
Kansas City, KS, 66160
Mailstop 3065
Office: +1 (913) 588-8223 | Fax: +1 (913) 588-4880 | Email: droblesmazzotti@kumc.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Text abstract and keywords

Background: Obesity is associated with obstructive sleep apnoea (OSA) and cardiovascular risk. Positive airway pressure (PAP) is the first line treatment for OSA, but evidence on its beneficial effect on major adverse cardiovascular events (MACE) prevention is limited. Using claims data, the effects of PAP on mortality and incidence of MACE among Medicare beneficiaries with OSA were examined.

Methods: A cohort of beneficiaries (>65 years) with ≥5 years of consecutive enrolment to Medicare and ≥2 distinct OSA claims was defined from multi-state, state-wide, multi-year (2011-2017) Medicare fee-for-service claims data. Evidence of PAP initiation and utilisation was based on PAP claims after OSA diagnosis. MACE was defined as a composite of myocardial infarction, heart failure, stroke, or coronary revascularisation. Doubly robust Cox proportional hazards models with inverse probability of treatment weights estimated treatment effects controlling for sociodemographic and clinical factors.

Results: Among 225,132 beneficiaries with OSA (median age 74 years; 45.3% women; median follow-up 3 years), those with evidence of PAP initiation (50.1%) had significantly lower all-cause mortality (HR [95%CI]: 0.57 [0.56-0.59]) and MACE incidence risk (0.90 [0.88-0.92]). Higher quartiles of annual PAP claims were progressively associated with lower mortality (Q2: 0.80 [0.75-0.86], Q3: 0.68 [0.64-0.72], Q4: 0.65 [0.61-0.70]) and MACE incidence risk (Q2: 0.91 [0.86-0.97], Q3: 0.87 [0.82-0.91], Q4: 0.85 [0.80-0.90]).

Conclusion: PAP utilisation was associated with lower all-cause mortality and MACE incidence among Medicare beneficiaries with OSA. Results might inform trials assessing the importance of OSA therapy towards minimising cardiovascular risk and mortality in older adults.

Keywords: obstructive sleep apnoea, positive airway pressure, Center for Medicare and Medicaid Services, cardiovascular disease, inverse probability of treatment weights.
Introduction

Obesity is a chronic condition with significant public health burden\(^1\), affecting 40% of adults in the U.S.\(^2\) and accounting for millions of cardiovascular (CV) disease deaths every year\(^3\). There is greater attention about the importance of adequate sleep habits\(^4\) and its relation to cardiometabolic risk\(^5,6\). Obstructive sleep apnoea (OSA) is a highly prevalent disorder contributing to these associations, with population rates of 9%-37% in men and 4-50% in women\(^7\), affecting nearly 1 billion people worldwide\(^8\). OSA becomes more prevalent with age\(^9,10\) and obesity\(^11\), and is associated with coronary heart disease, stroke, and CV mortality\(^12,13\). The CV risk due to OSA is greater among those with excessive sleepiness\(^14,15\), worse nocturnal hypoxemia\(^16\), and differential heart rate responses to respiratory events\(^17\). Thus, there is increasing attention on therapies that may modify CV risk for primary and secondary prevention\(^5,6,18\) through targeting sleep disordered breathing\(^19\).

Positive airway pressure (PAP) is the first line of therapy for moderate-severe OSA. Despite epidemiological studies strongly suggesting that OSA is a modifiable CV risk factor\(^20-26\), a meta-analysis of randomised controlled trials (RCTs) failed to demonstrate that PAP prevents CV outcomes\(^27\). Studies have shown that patient selection and treatment adherence may explain some of the negative results\(^28,29\). These challenges are intensified by the lack of large, equitable, and multi-centric pragmatic studies assessing the effectiveness of PAP on improving CV risk. Such studies are expensive and time-consuming, leading to recruitment and retention challenges, and delayed policy changes\(^31,32\). Whether long-term PAP therapy prevents CV disease in a clinical population is a critical question that remains unanswered.

Insurance claims data allow the design of observational studies that complement RCTs, by adopting causal inference methods\(^29,33,34\). When robustly applied, they have the potential to characterise the effect of OSA therapies in representative clinical settings\(^35\). A study on a French nationwide claims database found that continuous PAP (CPAP) therapy termination was
associated with all-cause mortality and incidence of heart failure\textsuperscript{36}. In the U.S., Centers for Medicare & Medicaid Services (CMS) beneficiaries represent a large population of older adults with access to healthcare coverage. Studies exploring a 5\% sample of randomly selected beneficiaries found that those with OSA had higher healthcare utilisation when compared to matched controls\textsuperscript{37}. Moreover, those adherent to CPAP based on Durable Medical Equipment (DME) claims were found to have reduced risk of stroke\textsuperscript{38} and healthcare expenses among those with pre-existing CV diseases\textsuperscript{39}. However, a major limitation is the reliance only on a sample of beneficiaries, which might represent challenges characterising the effects of PAP on the incidence of individual CV diseases with accuracy. State-wide Medicare claims, particularly within underserved states in the U.S., might reflect a broader representation of individuals with OSA and provide more generalisable effect estimates.

In this study, we aimed to determine the effect of PAP utilisation on all-cause mortality and incidence of MACE and its components among Medicare beneficiaries across 11 states in the Central U.S. By leveraging a robust causal inference design, we determined the average treatment effect of PAP initiation on the risk of incident MACE and mortality. Next, we established clinically relevant cut-offs of PAP utilisation based on DME claims over the first year after PAP initiation to determine PAP utilisation exposure groups. We demonstrate that these groups are differentially associated with incident MACE and mortality among older adults. Finally, we provide effect estimates of PAP exposure groups stratified by relevant sociodemographic and clinical factors.

\textbf{Methods}

Additional details are presented in the \textit{Supplemental materials}.

\textit{Study cohort}
Medicare beneficiaries (>65 years) with ≥5 years of consecutive enrolment to part A and B, and ≥2 distinct OSA claims were collected from multi-state, state-wide, multi-year (2011-2017) Medicare fee-for-service claims data. State-level Medicare claims data were originally obtained as part of the Greater Plains Collaborative Reusable Observable Unified Study Environment (GROUSE)\textsuperscript{40}, with a catchment area across 11 states in the Central U.S. The study protocol has been approved by Institutional Review Boards at each institution. The study cohort was defined based on a validated EHR algorithm to identify participants with OSA\textsuperscript{41} (see Supplemental Table 1). We further required >1 year enrolment with Medicare before their first OSA claim, to better capture newly diagnosed OSA and complete PAP utilisation history. For the analysis of incident MACE, we further excluded beneficiaries with history of MACE prior to their OSA diagnosis date.

Study design

This is an observational, retrospective analysis of state-wide Medicare claims data. We proposed two complementary causal inference designs to estimate the average treatment effect (ATE) of PAP initiation (Figure 1) and PAP utilisation exposure groups (Figure 2). For the PAP initiation analyses, prescription time-distribution matching\textsuperscript{42} was used to identify the “time zero” (exposure assignment, covariate determination, and start of follow-up) for the group that did not initiate PAP (pseudo landmark date, Figure 1), matched on the distribution of the time from diagnosis and start of PAP therapy in the group that initiated PAP (landmark T, Figure 1). For the analysis of PAP utilisation exposure groups, we included beneficiaries that have been enrolled and have not experienced events at the 1-year mark since their PAP initiation date. Exposure groups were defined based on the distribution of claim counts during this first year of PAP utilisation and “time zero” was the date of the first anniversary of PAP initiation (Figure 2).

PAP utilisation definitions
Evidence of PAP initiation was based on the first PAP initiation claim after OSA diagnosis (Supplemental methods). PAP utilisation exposure groups were used as surrogate measures of PAP adherence. We explored different surrogates based on the total count of PAP claims during first year of utilisation. Prior studies have suggested that a greater number of DME claims, such as mask refills, correlates with objective adherence based on hours of use\textsuperscript{43}. A comprehensive comparison of all methods is presented in the Supplemental methods and informed the selection of the quartile-based PAP utilisation exposure group definition, which was then used in our primary analysis.

**Study Outcomes**

We assessed two primary outcomes: all-cause mortality and incidence of MACE. All-cause mortality was obtained by identifying date of death provided in the Medicare beneficiary summary file. MACE was defined as a composite of first occurrence of myocardial infarction (MI), heart failure (HF), stroke or coronary revascularisation, identified by diagnostic and procedure codes (Supplemental Table 1). Secondary analyses using each component of MACE as outcomes are also presented.

**Covariates**

We included the following covariates: age, sex, race (White, Black, American Indian, Asian, Other), socioeconomic status, prior history of type 2 diabetes, hypertension, obesity, MACE (only in models assessing all-cause mortality), chronic obstructive pulmonary disease (COPD), hypersomnia, and insomnia (see Supplemental Table 1 for definitions).

**Statistical analyses**

Sociodemographic characteristics and clinical history were described between PAP initiation exposure groups using counts and percentages for categorical data and median and
interquartile range for continuous data. Univariate associations between sociodemographic and clinical history variables with PAP initiation exposure groups were performed using chi-squared tests. We used Kaplan-Meier survival analyses and log-rank tests to compare survival curves between PAP initiation exposure groups for MACE and all-cause mortality. We assessed the proportional hazards assumption by assessing scaled Schoenfeld residuals, which did not find strong evidence of violation. We implemented a causal inference framework to determine the effect of PAP initiation or PAP utilisation exposure groups on the outcomes of interest (all-cause mortality and MACE). Specific details are presented in the Supplemental methods. Briefly, we derived propensity scores (PS) based on PAP initiation or utilisation, and then calculated weights that were used in fully adjusted weighted Cox regression models assessing the effect of PAP initiation or PAP utilisation exposure groups on the outcomes of interest, representing causal estimate of the ATE derived from a doubly robust estimator. This framework was applied to our primary analyses, as well as to secondary analyses assessing individual components of MACE. Results of stratified analysis by sociodemographic and clinical characteristics are also presented. We determined statistical significance based on Bonferroni-corrected thresholds of \( p<0.025 \) (2 primary outcomes) and provide E-values to assess the strength of association a potential unmeasured confounder would need to express to nullify observed associations.

Results

Sample characterisation

Our sample included 225,132 eligible Medicare beneficiaries with evidence of OSA diagnosis (median [Q1, Q3] age 74 [71, 79] years; 45.3% women; median [Q1, Q3] follow-up 3.9 [1.9, 4.7] years). Figure 3 shows the study flowchart. Among eligible participants, 112,703 (50.1%) had evidence of PAP initiation. Table 1 shows the sample characteristics according to PAP initiation groups. Participants that have initiated PAP were younger, more likely to be men and White, more likely to have been diagnosed with hypersomnia and less likely to be
diagnosed with COPD, type 2 diabetes, hypertension, and to have had a first MACE at OSA diagnosis. Overall, 5-year cumulative mortality rate was 18.2% (based on total N=225,132) and 5-year cumulative MACE incidence was 43.6% (based on those without MACE at baseline, N=139,663). When stratified by PAP initiation exposure groups, those who initiated PAP had a 5-year cumulative mortality rate and cumulative MACE incidence of 13.1% and 41.4% respectively. Those who did not initiate PAP had a 5-year incidence rates of mortality and MACE event of 23.5% and 46.2%, respectively (p<0.001 for both).

**PAP initiation is associated with greater survival and MACE-free probability**

Kaplan-Meier survival curves for all-cause mortality and MACE, according to PAP initiation exposure groups are presented in **Figure 4**. Log-rank test indicates significant differences in all-cause mortality and MACE-free survival probabilities (p<0.001), with participants that have initiated PAP presenting greater survival than those without.

**PAP initiation is independently associated with lower mortality and lower incidence of MACE**

Results of doubly robust Cox proportional hazards models are presented in **Figure 5**, Stratification: None. Patients with evidence of PAP initiation had significantly lower all-cause mortality risk (HR [95%CI] = 0.57 [0.56-0.59]; p<0.001) and lower MACE incidence risk (0.90 [0.88-0.92]; p<0.001) when compared to those without evidence of initiating PAP. The risk ratio of an unmeasured confounder (E-value) would need to be 2.90 to explain away the effect of PAP initiation on mortality, and 1.36 to explain away the effect on MACE.

Analyses of secondary outcomes (MI, HF, stroke, and coronary revascularisation) are presented in **Supplemental Figure 1**. OSA patients with evidence of PAP initiation had significantly lower incidence risk of MI (0.84 [0.81-0.87]; p<0.001; E-value: 1.67), HF (0.91 [0.89-0.93]; p<0.001; E-value: 1.43), and stroke (0.84 [0.81-0.87]; p<0.001; E-value: 1.67). No association with incident coronary revascularisation was observed (0.96 [0.92-1.00]; p=0.055).
Next, we investigated whether the effect of PAP initiation was consistent across subgroups of sociodemographic and clinical factors. Results of primary outcomes are presented in Figure 5 and of secondary outcomes are presented in Supplemental Figure 1. We observed that effect estimates regarding all-cause mortality are consistent across subgroups, with significantly lower risk among those that initiated PAP across all strata, and key differences in certain subgroups. We observed stronger protective effects of PAP initiation among those 70 years or older (70-74 years: 0.58 [0.56-0.60]; 75-79 years: 0.56 [0.54-0.58]; 80+: 0.55 [0.54-0.57], as compared to those 65-69 years (0.69 [0.65-0.73]). Similar trends were observed among women (0.55 [0.54-0.57]) as compared to men (0.59 [0.57-0.60]), those with lower social economic status (0.55 [0.54-0.57]) as compared to those with higher (0.59 [0.57-0.60]), those with evidence of obesity diagnosis (0.52 [0.50-0.53]) as compared to those without (0.60 [0.59-0.61]), those with evidence of history of MACE (0.55 [0.54-0.57]) as compared to those without (0.61 [0.59-0.63]), and those without evidence of hypersomnia (0.57 [0.56-0.58]) as compared to those with (0.69 [0.62-0.76]).

Regarding incidence of MACE, we only observed significant PAP initiation effects among those 70 years or older (70-74 years: 0.89 [0.87-0.91]; 75-79 years: 0.89 [0.87-0.92]; 80+: 0.87 [0.85-0.89], as compared to those 65-69 years (0.97 [0.94-1.00]). We also observed slightly stronger protective effects of PAP initiation among women (0.88 [0.86-0.90]) as compared to men (0.92 [0.90-0.93]), those with lower social economic status (0.85 [0.83-0.87]) as compared to those with higher (0.92 [0.91-0.94]), those with evidence of obesity diagnosis (0.86 [0.83-0.88]) as compared to those without (0.91 [0.90-0.93]), and those with evidence of COPD diagnosis (0.87 [0.85-0.90]) as compared to those without (0.91 [0.90-0.92]).

Stratified analyses regarding secondary outcomes (MACE components) consistently showed significantly lower incidence of MI, HF, and stroke across all subgroups of sociodemographic and clinical factors, with no consistent differences regarding coronary revascularisation procedures (Supplemental Figure 1). Important differences were observed
for certain subgroups. Regarding MI, strongest beneficial effects of PAP initiation were observed among those with 70-74 years (0.79 [0.76-0.83]), those with lower social economic status (0.78 [0.75-0.81]), and those with evidence of hypertension diagnosis (0.82 [0.80-0.95]). Regarding HF, strongest beneficial effects of PAP initiation were observed in those 70 years or older (70-75 years: 0.92 [0.89-0.94]; 75-79 years: 0.89 [0.86-0.92]; 80+ years: 0.86 [0.83-0.88]), those with lower social economic status (0.85 [0.83-0.87]), and those with evidence of obesity diagnosis (0.87 [0.84-0.90]). Regarding stroke, strongest beneficial effects of PAP initiation were observed among those with 70-74 years (0.83 [0.80-0.87]), women (0.81 [0.78-0.84]), and among those with evidence of type 2 diabetes diagnosis (0.81 [0.78-0.84]). Regarding coronary revascularisation, strongest beneficial effects of PAP initiation were observed among those with 70-74 years (0.90 [0.86-0.94]).

_Determination of first year PAP utilisation exposure groups_

To inform our proposed analysis assessing the effect of PAP utilisation exposure groups, we first observed the distribution of total PAP claims per patient at the end of first year of PAP utilisation (Supplemental Figure 2). PAP claim counts showed a bimodal distribution, suggesting two utilisation patterns were more prevalent: a mode on 4 claims and a mode on 15 claims, which may be suggestive of CMS PAP reimbursement models and may correlate with PAP adherence. Because Medicare claims databases do not include PAP adherence tracking, we explored different PAP exposure group definitions (see _PAP utilisation definitions_ and Supplemental Figure 3) to determine relevant cut-offs in the distribution of PAP claims. We further assessed associations between different PAP exposure group definitions and our primary and secondary outcomes. In general, a greater count of PAP claims during the first year was progressively associated with lower all-cause mortality and lower MACE incidence risk (Supplemental Figure 4), as well as lower incident MI, HF, and stroke (Supplemental Figure 5), reaching a plateau after approximately 14-16 claims. When using the numeric count of PAP
claims as our exposure, each additional PAP claim was significantly associated with lower hazards of all-cause mortality (0.97 [0.96-0.97]), MACE (0.99 [0.99-0.99]), MI (0.99 [0.98-0.99]), HF (0.99 [0.98-0.99]) and stroke (0.98 [0.97-0.98]), but not with coronary revascularisations (1.00 [0.99-1.01]). To address the non-linearity of the associations between PAP claim counts and outcomes, we performed spline extrapolation analyses and estimated the HR as a function of PAP claim counts (Supplemental Figure 6). Results suggest HR estimates are the highest (e.g., greater hazards) around 4-9 PAP claims and lowest at 18-20 PAP claims across all study outcomes. Taken together, these exploratory analyses helped to inform us that using a quartile-based definition of PAP exposure groups based on claim counts (Q1: 1 to 11 claims; Q2: 12 to 14 claims; Q3: 15 to 16 claims; and Q4: >16 claims) provided a realistic representation of PAP utilisation patterns that demonstrated clinically relevant variation in incident outcome risk. Therefore, we focused the description of the following results based on this definition.

Greater PAP utilisation is progressively associated with lower risk of mortality and MACE

Results of doubly robust Cox proportional hazards models assessing the effect of PAP utilisation exposure groups based on quartiles of PAP claim counts on all-cause mortality and incidence of MACE are presented in Figure 6 (among all participants [Stratification: None] and stratified by sociodemographic characteristics) and Figure 7 (stratified by comorbidities), and results for secondary outcomes are presented in Supplemental Figure 7 and 8. Among patients with OSA and with evidence of PAP utilisation in their first year of therapy, higher quartiles of claim counts (i.e., higher PAP utilisation) were progressively associated with lower all-cause mortality (Q2: 0.80 [0.75-0.86], Q3: 0.68 [0.64-0.72], Q4: 0.65 [0.61-0.70]) and lower MACE incidence (Q2: 0.91 [0.86-0.97], Q3: 0.87 [0.82-0.91], Q4: 0.85 [0.80-0.90]), when compared to those with ≤11 PAP claims in their first year. Similar results were observed for secondary outcomes, with lower MI incidence risk on Q3 (0.85 [0.76-0.96]) and Q4 (0.81 [0.72-0.92]), lower HF incidence risk (Q2: 0.89 [0.82-0.95], Q3: 0.83 [0.78-0.89], Q4: 0.84 [0.78-0.90])
and lower stroke incidence risk (Q2: 0.81 [0.73-0.91], Q3: 0.82 [0.75-0.91], Q4: 0.74 [0.66-0.82]). No evidence of association with incident coronary revascularisation was observed (Supplemental Figure 7).

Analyses stratified by sociodemographic characteristics (Figure 6 and Supplemental Figure 7) and comorbidities (Figure 7 and Supplemental Figure 8) were consistent overall, supporting the protective effects of higher PAP claim counts against all-cause mortality and incident MACE across several strata. Exceptions include certain race groups and those with positive history of hypersomnia, likely due to the limited sample size of subgroups resulting in wide confidence intervals and less accurate estimates. Regarding all-cause mortality, key differences across strata include stronger protective effects of higher PAP utilisation among those with 65-69 years, and those with evidence of insomnia. Regarding MACE, stronger protective effects of higher PAP utilisation were observed among those with 65-69 years, women, those with lower socioeconomic status, those without history of hypertension, and those without evidence of insomnia. Regarding MI, stronger protective effects of higher PAP utilisation were observed among those with 70-74 years and >80 years, women, those with lower socioeconomic status, those without evidence of obesity, those with history of type 2 diabetes and those without evidence of insomnia. Regarding HF, stronger protective effects of higher PAP utilisation were observed among those with 65-69 years, men (except for >16 claims), those with lower socioeconomic status, those without history of hypertension, and those without evidence of insomnia. Regarding stroke, protective effects of higher PAP utilisation were observed among those with 65-69 years, women, those with lower socioeconomic status (>16 claims only), those with evidence of COPD (>16 claims only), and those with history of hypertension. Finally, regarding coronary revascularisation procedures, protective effects of higher PAP utilisation were only observed among those with 65-69 years, women (except 15-16 claims), and those with lower socioeconomic status. Effects estimates and confidence intervals are shown in Figures 6 and 7, and Supplemental Figures 7 and 8.
Discussion

This study provided a systematic assessment of the effects of PAP initiation and utilisation on MACE and mortality among older adults that are Medicare beneficiaries across 11 states in the U.S. Our main findings suggest significant associations between claims-based PAP initiation and utilisation and lower all-cause mortality and incidence of MACE. Associations of PAP initiation and utilisation were also significant for MACE components, with consistent effects on MI, HF, and stroke. We observed that PAP initiation effects were stronger in women and in those 70 years or older, with lower socioeconomic status and with clinical comorbidities. Higher PAP utilisation exposure groups were progressively associated with lower incidence of primary (i.e., mortality, MACE) and secondary (i.e., MI, HF, stroke) outcomes, with consistent effects in stratified analysis, but with particularly stronger beneficial effects among those between 65-69 years, women, and those with lower socioeconomic status. We used a robust causal inference framework to minimise immortal time bias and provided more reliable estimates of treatment effects. Results from this observational study might inform future trials assessing the importance of OSA therapy initiation and maintenance towards minimising CV risk and mortality in older adults.

Extensive epidemiological evidence suggests that moderate-severe OSA is associated with hypertension\textsuperscript{49-51}, stroke\textsuperscript{26}, atrial fibrillation\textsuperscript{52} MI\textsuperscript{53}, and CV mortality\textsuperscript{54}. Several mechanisms may explain the relationship between OSA and CV diseases, including sympathetic activation, endothelial dysfunction, oxidative stress, systemic inflammation, cardiac remodelling due to hypoxemia, intrathoracic pressure swings and changes in blood pressure\textsuperscript{55}. These overlapping mechanisms indicate that therapies targeting OSA are likely to be beneficial towards CV disease prevention. RCTs have established that PAP improves daytime symptoms, mood, and quality of life\textsuperscript{56,57}, and reduces systolic and diastolic blood pressure\textsuperscript{49}, especially in patients with resistant hypertension\textsuperscript{51}. PAP therapy has positive effects on long-term survival in patients with...
ischemic stroke and moderate-severe OSA and it has been associated with lower rate of fatal and non-fatal CV events over a 10-year follow-up.

Despite this consistent evidence, recent RCTs investigating the effect of CPAP on different fatal and non-fatal CV events were negative. A careful investigation of the limitations in these trials has suggested that patient selection and treatment adherence may have played an important role on explaining differences between RCTs and observational studies. In fact, only 20% of patients seeking care in sleep clinics would be eligible to participate in these RCTs. Many patients present with excessive daytime sleepiness, which was an important exclusion criterion in these trials, due to the ethical reason of randomising patients that are excessively sleepy into control arms. However, we and others have demonstrated this subgroup is at increased risk for incident CV diseases. These observations suggest that alternative approaches using causal inference in well-designed observational studies could provide more generalisable evidence towards the role of PAP therapy on CV outcomes risk.

Exploring ‘real-world data’ approaches using robust statistical methods that minimise biases and confounding issues that are inherent to observational studies may help inform evidence generation in a more timely and cost-effective manner. The success of these approaches has been demonstrated by the current investigation, as it provided relevant and generalisable evidence about the beneficial effects of PAP initiation and utilisation in a defined population of older adults in the U.S.. It has also been demonstrated by recent studies exploring the role of CPAP on risk of mortality, HF, stroke, reduced health-care utilisation and related expenses among those with pre-existing CV diseases, including HF with reduced ejection fraction. In the context of a recently published report from the AHRQ suggesting a lack of strong evidence supporting the role of PAP on long-term CV outcomes, these studies are fundamental to fill this evidence gap.

Our study has identified important associations within subgroups. Notably, we observed greater beneficial effects of PAP initiation on mortality and MACE among older adults ≥70 years,
suggesting that primary CV prevention among those with newly diagnosed OSA at older ages could be beneficial. However, these results are conflicting with a 3-month RCT of CPAP therapy among elderly adults >70 years with moderate-severe OSA, which did not find significant effects on blood pressure levels or neurocognitive tests, although significant improvements in sleepiness were observed. A secondary analysis of this trial, only among those >80 years, did not find significant effects on sleepiness. Among those that initiated PAP therapy, our study found greater beneficial effects of PAP utilisation in those that are 65-69 years. Differences may be explained by length of follow-up and study design considerations. Future trials assessing the role of PAP therapy on the health of older adults using longer follow-up times are warranted. We also observed stronger PAP initiation and greater utilisation effects on mortality and MACE among women, in agreement with prior studies, particularly post-menopause. It is likely that women are subjected to stronger acute detrimental effects of OSA following menopause, and therefore might experience stronger therapeutic effects. Women with OSA are also more likely to have comorbid metabolic conditions. However, little is known about sex differences in PAP treatment responses, particularly at older ages. Patients with lower socioeconomic status may be less receptive to receiving PAP therapy and report poorer treatment adherence. Yet, our results demonstrate that those with low-income subsidy and dual Medicare/Medicaid eligibility have greater benefit of PAP against mortality and MACE. These results highlight opportunities to implement care programs designed to minimise health disparities, as recently proposed. Our study also identified stronger effects of PAP initiation among those with comorbid conditions such as obesity, COPD, and type 2 diabetes. It is likely that these subgroups are at a greater underlying risk with the added comorbid impact, and therefore therapy benefit might be greater. Importantly, subgroups with evidence for comorbidities might also represent patients at highest risk for early termination of CPAP, which suggests that efforts to support therapy continuation might be beneficial particularly for these patients. We also found stronger beneficial effects of PAP initiation among those without evidence of hypersomnia, which contradicts the
well-established relationship between excessive daytime sleepiness and increased CV risk among those with OSA. However, granular measures of excessive daytime sleepiness might provide a more robust phenotype when compared to claims for hypersomnia. Only ~6% of our study cohort had evidence of hypersomnia, which suggests it might not capture all patients with the excessively sleepy phenotype. In summary, these results might help guide future RCTs assessing the role of PAP initiation and/or strategies to increase PAP adherence among higher-risk subgroups.

This study utilised state-wide Medicare claims data to determine the effects of PAP initiation and utilisation on outcomes. While we acknowledge that objective definitions of PAP adherence and efficacy are still preferred to estimate exposure to PAP, telemonitoring data has only become available in recent years. Prior studies have investigated similar PAP exposure definitions in a nationwide claims database in France and within 5% Medicare beneficiaries samples in the U.S., and reported consistent results as with objective PAP adherence data. From an epidemiologic perspective, state-wide claims databases cover a large proportion of the older adult demographic and offer a scalable approach to identify those likely to be exposed to PAP independently of vendor or telemonitoring capabilities, thus maximising generalisability. A single-site study comparing objective adherence based on hours of use found that mask refill claims positively correlated with PAP utilisation. To provide further information about PAP utilisation based on claims, our study presented a detailed assessment of different PAP utilisation exposure group definitions. We observed a bimodal distribution of PAP claim counts within the first year since PAP initiation, which is suggestive of recognised CMS reimbursement models. CMS reimburses PAP therapy among eligible beneficiaries in monthly instalments; when a patient does not meet the eligibility criteria for continued therapy at the third month of utilisation, the device is not reimbursed, and no further claims will be identified. We speculate that the first mode of the distribution (4 claims) may represent patients that did not meet the CMS criteria for adherence and therefore may present lower overall PAP utilisation.
1 during their first year. Similarly, the second mode (15 claims) may represent patients that have
demonstrated early adherence and continued to use PAP throughout the year. Our results are
consistent with this definition, as it suggests that greater number of PAP claims are associated
with greater beneficial outcomes. Therefore, while large scale multisite studies predicting short-
and long-term objective PAP adherence using claims data are still needed, the definitions used
in our study seem to capture relevant clinical outcomes regarding PAP utilisation.

Our study has important limitations. First, our cohort identification approach was based
on ICD codes, available through a Medicare claims database, thus preventing characterisation
of disease severity based on the apnoea-hypopnea index (AHI) or other novel physiological
traits that have been recently demonstrated to be important for CV risk stratification, such as
hypoxic burden\(^{16}\) and heart rate responses to events\(^{17}\). However, we used an algorithm
validated in different clinical sites that demonstrated excellent predictive performance\(^{41}\),
suggesting that our cohort definition reliably captured individuals with OSA. Second, as
previously discussed, our claims-based PAP utilisation definition may not accurately represent
more objective definitions of PAP use. However, hours of use (often used as the only exposure
when telemonitoring data is available) may not be the only determinant of PAP efficacy, as other
factors such as proportion of protected sleep time (e.g., how many hours sleep on efficacious
PAP relative to total sleep time), efficacy of therapy reflected by the optimal pressure, minimal
leak, and minimal residual AHI, and even timing of PAP utilisation during the night (e.g., early
morning termination of therapy might induce more severe rapid eye movement sleep AHI
reducing overall PAP efficacy\(^{80,81}\)), might be more important predictors of successful therapy,
and are yet to be consistently assessed in telemonitoring studies. We encourage that PAP
vendors expand academic-industry partnerships towards facilitating privacy-preserving linkage
of PAP telemonitoring databases with more granular information from EHR, claims, patient
reported outcomes and wearables. Such approaches will be fundamental in future studies
aimed at determining the effects of PAP therapy on both short- and long-term clinical outcomes.
Third, our covariate definition was based only on claims data, and lack granular information about other relevant confounders such as body mass index, blood pressure, and laboratory measurements that are predictive of CV risk. Moreover, other important factors such as diet, physical activity, and healthy adherer behaviours\textsuperscript{62} were not available and could explain some of the observed effects. To mitigate this limitation, we provide E-values as a guide to understand the impact of a potential unmeasured confounders in our reported associations. Results suggest that unmeasured confounders with effects (in the risk ratio scale) as large as 2.90 for all-cause mortality and 1.36 for MACE would have to be observed, after adjustment for other covariates, to explain away associations with our primary outcomes. Finally, the present study focuses on a population of older adults that are Medicare beneficiaries in the Central U.S., and extrapolation of effect estimates to other demographics cannot be made. In one hand, studies in mid-life adults would provide important insights about OSA natural history and early prevention of CV outcomes. On the other hand, our study is generalisable to a very large proportion of older adults, as >95% of those >65 years in the Unites States are enrolled in Medicare. There is also greater confidence in the ascertainment of outcomes.

In conclusion, PAP utilisation based on claims was associated with lower all-cause mortality and MACE incidence (including MI, HF, and stroke) among Medicare beneficiaries >65 years. Results support the hypothesis that PAP has beneficial effects against mortality and CV diseases. This study has the potential to inform future trials assessing the importance of OSA therapy initiation and maintenance towards minimising adverse health outcomes in older adults leading to longer and healthier lives. These results may also inform strategies to improve adherence and efficacy of PAP therapy there are patient-specific, towards personalised sleep medicine.

Acknowledgements
The authors would like to acknowledge the technical and scientific resources and support from the Greater Plains Collaborative team members, as well as all Medicare beneficiaries whose data were contributing to this investigation.

**Funding**

The study was funded by the American Heart Association (20CDA35310360), Patient-Centered Outcomes Research Institute (RI-CRN-2020-003-IC); NIH CTSA NCATS Frontiers: University of Kansas Clinical and Translational Science Institute (UL1TR002366); Tier 2 grant, University of Missouri.

**Conflict of interest statement**

Dr. Krishna Sundar was a past advisory board member for Resmed Inc. and is the co-founder of Hypnoscure LLC through the University of Utah Technology Commercialization Office All other authors declared no conflicts of interest.

**Data availability statement**

The data underlying this article cannot be shared publicly to protect the privacy of individuals that participated in the study, as stipulated by each institution of the Greater Plains Collaborative. There are established processes for interested investigators to collaborate with the Greater Plains Collaborative research network, that can be accessed via this URL: https://gpcnetwork.org/.

**Notes**

*Greater Plains Collaborative:* Sravani Chandaka, Kelechi (KayCee) Anuforo, Lav Patel, Daryl Budine, Nathan Hensel, Siddharth Satyakam, Sharla Smith, Dennis Ridenour, Cheryl Jernigan, Carol Early, Kyle Stephens, Kathy Jurius, Abbey Sidebottom, Cassandra Rodgers, Hong Zhong,
References


7. Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population—a review on the epidemiology of sleep apnea. J Thorac Dis 2015;7:1311-1322. doi: 10.3978/j.issn.2072-1439.2015.06.11


32. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. *Contemporary Clinical Trials Communications* 2018;11:156-164. doi: 10.1016/j.conctc.2018.08.001


48. Patel N, Sam A, Valentin A, Quan SF, Parthasarathy S. Refill Rates of Accessories for Positive Airway Pressure Therapy as a Surrogate Measure of Long-Term Adherence. *Journal of Clinical Sleep Medicine* 2012;08:169-175. doi: 10.5664/jcsm.1772


58. Lyons OD, Ryan CM. Sleep Apnea and Stroke. *Can J Cardiol* 2015;31:918-927. doi: 10.1016/j.cjca.2015.03.014


65. Malhotra A, Cole KV, Malik AS, et al. Positive Airway Pressure Adherence and Heart Failure Utilization in Patients With Obstructive Sleep Apnea and Heart Failure With
Reduced Ejection Fraction. *Journal of the American Heart Association* 2023;12. doi: 10.1161/jaha.122.028732


Figure Legends

Figure 1. Overview of the PAP initiation analysis study design.

Figure 2. Overview of the PAP utilisation exposure group study design.

Figure 3. Study cohort definitions and CONSORT diagram.

Figure 4: Unadjusted and adjusted Kaplan-Meier survival curves describing the survival probabilities between PAP initiation exposure groups and all-cause mortality (top) and MACE (bottom). Numbers in boxes represent annual survival probabilities per group. The results of log-rank tests comparing exposure groups are also shown.

Figure 5. Summary of IPTW-adjusted Cox proportional hazards models assessing the effect of PAP initiation on all-cause mortality (ACM) and MACE in all eligible participants (Stratification: None) and within categories of relevant sociodemographic and clinical characteristics. Results were derived from IPTW-weighted Cox proportional hazards models adjusted for age, sex, race, low-income-subsidy or dual-eligibility indicator, type 2 diabetes, hypertension, obesity, MACE (all-cause mortality only), COPD, hypersomnia, and insomnia. Among stratified models, stratification variable was not included as a covariate in propensity score models nor in outcome models. Reference category is no evidence of PAP initiation. Abbreviations: ACM: all-cause mortality; COPD: chronic obstructive pulmonary disease; PAP: positive airway pressure; HR: hazard ratio; CI: confidence interval; MACE: major adverse cardiovascular event; IPTW: inverse probability of treatment weights.

Figure 6. Summary of IPTW-adjusted Cox proportional hazards models assessing the effect of PAP utilisation exposure groups based on quartiles of PAP claim counts on all-cause mortality.
(ACM) and MACE among all participants and stratified by sociodemographic variables. PAP exposure groups were defined as follows: Q1 (reference): 1-11 claims; Q2: 12-14 claims; Q3: 15-16 claims; Q4: >16 claims). Results were derived from IPTW-weighted Cox proportional hazards models adjusted for age, sex, race, low-income-subsidy or dual-eligibility indicator, type 2 diabetes, hypertension, obesity, MACE (all-cause mortality only), COPD, hypersomnia, and insomnia. Among stratified models, stratification variable was not included as a covariate in propensity score models nor in outcome models. Abbreviations: ACM: all-cause mortality; COPD: chronic obstructive pulmonary disease; PAP: positive airway pressure; HR: hazard ratio; CI: confidence interval; MACE: major adverse cardiovascular event; IPTW: inverse probability of treatment weights.

**Figure 7.** Summary of IPTW-adjusted Cox proportional hazards models assessing the effect of PAP utilisation exposure groups based on quartiles of PAP claim counts on all-cause mortality (ACM) and MACE stratified by comorbidities. PAP exposure groups were defined as follows: Q1 (reference): 1-11 claims; Q2: 12-14 claims; Q3: 15-16 claims; Q4: >16 claims). Results were derived from IPTW-weighted Cox proportional hazards models adjusted for age, sex, race, low-income-subsidy or dual-eligibility indicator, type 2 diabetes, hypertension, obesity, MACE (all-cause mortality only), COPD, hypersomnia, and insomnia. Among stratified models, stratification variable was not included as a covariate in propensity score models nor in outcome models. Abbreviations: ACM: all-cause mortality; COPD: chronic obstructive pulmonary disease; PAP: positive airway pressure; HR: hazard ratio; CI: confidence interval; MACE: major adverse cardiovascular event; IPTW: inverse probability of treatment weights.
<table>
<thead>
<tr>
<th>Stratification</th>
<th>ACM...</th>
<th>ACM.HR (95% CI)</th>
<th>MACE...</th>
<th>MACE.HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01. None</td>
<td></td>
<td>0.57 (0.56-0.59)</td>
<td>***</td>
<td>0.90 (0.88-0.92)</td>
</tr>
<tr>
<td>02. Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-69 years</td>
<td></td>
<td>0.69 (0.65-0.73)</td>
<td>***</td>
<td>0.97 (0.94-1.00)</td>
</tr>
<tr>
<td>70-74 years</td>
<td></td>
<td>0.58 (0.56-0.60)</td>
<td>***</td>
<td>0.89 (0.87-0.91)</td>
</tr>
<tr>
<td>75-79 years</td>
<td></td>
<td>0.56 (0.54-0.58)</td>
<td>***</td>
<td>0.89 (0.87-0.92)</td>
</tr>
<tr>
<td>80+ years</td>
<td></td>
<td>0.55 (0.54-0.57)</td>
<td>***</td>
<td>0.87 (0.85-0.89)</td>
</tr>
<tr>
<td>03. Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>0.55 (0.54-0.57)</td>
<td>***</td>
<td>0.88 (0.86-0.90)</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>0.59 (0.57-0.60)</td>
<td>***</td>
<td>0.92 (0.90-0.93)</td>
</tr>
<tr>
<td>04. Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td></td>
<td>0.55 (0.50-0.59)</td>
<td>***</td>
<td>0.92 (0.86-0.99)</td>
</tr>
<tr>
<td>Native American</td>
<td></td>
<td>0.68 (0.48-0.96)</td>
<td></td>
<td>1.07 (0.83-1.38)</td>
</tr>
<tr>
<td>Asian</td>
<td></td>
<td>0.58 (0.46-0.74)</td>
<td>***</td>
<td>1.02 (0.87-1.21)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>0.62 (0.43-0.88)</td>
<td>*</td>
<td>1.04 (0.84-1.29)</td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td>0.58 (0.54-0.63)</td>
<td>***</td>
<td>0.95 (0.90-1.01)</td>
</tr>
<tr>
<td>White</td>
<td></td>
<td>0.57 (0.56-0.59)</td>
<td>***</td>
<td>0.89 (0.88-0.91)</td>
</tr>
<tr>
<td>05. Low-income-subsidy/Dual Eligibility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>0.59 (0.57-0.60)</td>
<td>***</td>
<td>0.92 (0.91-0.94)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>0.55 (0.54-0.57)</td>
<td>***</td>
<td>0.85 (0.83-0.87)</td>
</tr>
<tr>
<td>06. Obesity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>0.60 (0.59-0.61)</td>
<td>***</td>
<td>0.91 (0.90-0.93)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>0.52 (0.50-0.53)</td>
<td>***</td>
<td>0.86 (0.83-0.88)</td>
</tr>
<tr>
<td>07. COPD History</td>
<td></td>
<td>0.57 (0.56-0.58)</td>
<td>***</td>
<td>0.91 (0.90-0.92)</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>0.58 (0.56-0.59)</td>
<td>***</td>
<td>0.87 (0.85-0.90)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>0.56 (0.55-0.58)</td>
<td>***</td>
<td>0.87 (0.85-0.90)</td>
</tr>
<tr>
<td>08. Hypertension History</td>
<td></td>
<td>0.57 (0.56-0.58)</td>
<td>***</td>
<td>0.87 (0.85-0.90)</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>0.63 (0.59-0.68)</td>
<td>***</td>
<td>0.88 (0.85-0.91)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>0.56 (0.55-0.58)</td>
<td>***</td>
<td>0.87 (0.85-0.90)</td>
</tr>
<tr>
<td>09. T2DM History</td>
<td></td>
<td>0.57 (0.56-0.58)</td>
<td>***</td>
<td>0.90 (0.89-0.92)</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>0.63 (0.59-0.68)</td>
<td>***</td>
<td>0.88 (0.85-0.91)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>0.56 (0.55-0.58)</td>
<td>***</td>
<td>0.87 (0.85-0.90)</td>
</tr>
<tr>
<td>10. MACE History</td>
<td></td>
<td>0.61 (0.59-0.63)</td>
<td>***</td>
<td>0.90 (0.89-0.92)</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>0.61 (0.59-0.63)</td>
<td>***</td>
<td>0.90 (0.89-0.92)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>0.59 (0.57-0.60)</td>
<td>***</td>
<td>0.90 (0.89-0.92)</td>
</tr>
<tr>
<td>11. Hypersomnia</td>
<td></td>
<td>0.57 (0.56-0.58)</td>
<td>***</td>
<td>0.90 (0.89-0.92)</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>0.57 (0.56-0.58)</td>
<td>***</td>
<td>0.90 (0.89-0.92)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>0.69 (0.62-0.76)</td>
<td>***</td>
<td>0.89 (0.84-0.95)</td>
</tr>
<tr>
<td>12. Insomnia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
<td>0.57 (0.56-0.58)</td>
<td>***</td>
<td>0.90 (0.89-0.92)</td>
</tr>
<tr>
<td>Yes</td>
<td></td>
<td>0.56 (0.53-0.59)</td>
<td>***</td>
<td>0.89 (0.85-0.93)</td>
</tr>
<tr>
<td>Stratiﬁcation</td>
<td>ACM...</td>
<td>ACM.HR (95% CI)</td>
<td>MACE...</td>
<td>MACE.HR (95% CI)</td>
</tr>
<tr>
<td>---------------</td>
<td>--------</td>
<td>-----------------</td>
<td>---------</td>
<td>-----------------</td>
</tr>
<tr>
<td>06. Obesity: No</td>
<td>Q2 (12 - 14)</td>
<td>0.75 (0.72 - 0.78)</td>
<td>0.92 (0.90 - 0.95)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.66 (0.63 - 0.70)</td>
<td>0.88 (0.85 - 0.91)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.62 (0.59 - 0.65)</td>
<td>0.84 (0.81 - 0.87)</td>
<td>****</td>
</tr>
<tr>
<td>06. Obesity: Yes</td>
<td>Q2 (12 - 14)</td>
<td>0.90 (0.85 - 0.95)</td>
<td>0.99 (0.96 - 0.99)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.71 (0.66 - 0.75)</td>
<td>0.94 (0.90 - 0.98)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.71 (0.67 - 0.75)</td>
<td>0.97 (0.93 - 0.99)</td>
<td>***</td>
</tr>
<tr>
<td>07. COPD History: No</td>
<td>Q2 (12 - 14)</td>
<td>0.78 (0.75 - 0.81)</td>
<td>0.91 (0.88 - 0.93)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.68 (0.65 - 0.71)</td>
<td>0.97 (0.93 - 0.99)</td>
<td>***</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.66 (0.63 - 0.69)</td>
<td>0.85 (0.82 - 0.88)</td>
<td>****</td>
</tr>
<tr>
<td>07. COPD History: Yes</td>
<td>Q2 (12 - 14)</td>
<td>0.85 (0.80 - 0.91)</td>
<td>0.90 (0.84 - 0.96)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.68 (0.63 - 0.73)</td>
<td>0.94 (0.77 - 0.91)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.64 (0.60 - 0.69)</td>
<td>0.88 (0.80 - 0.94)</td>
<td>**</td>
</tr>
<tr>
<td>08. Hypertension History: No</td>
<td>Q2 (12 - 14)</td>
<td>0.64 (0.56 - 0.74)</td>
<td>0.82 (0.75 - 0.89)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.58 (0.49 - 0.68)</td>
<td>0.81 (0.74 - 0.90)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.53 (0.45 - 0.62)</td>
<td>0.75 (0.68 - 0.83)</td>
<td>***</td>
</tr>
<tr>
<td>08. Hypertension History: Yes</td>
<td>Q2 (12 - 14)</td>
<td>0.81 (0.79 - 0.84)</td>
<td>0.92 (0.90 - 0.94)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.68 (0.66 - 0.71)</td>
<td>0.95 (0.88 - 0.99)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.66 (0.64 - 0.69)</td>
<td>0.86 (0.84 - 0.89)</td>
<td>**</td>
</tr>
<tr>
<td>09. T2DM History: No</td>
<td>Q2 (12 - 14)</td>
<td>0.74 (0.71 - 0.78)</td>
<td>0.91 (0.89 - 0.93)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.62 (0.58 - 0.65)</td>
<td>0.87 (0.84 - 0.90)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.63 (0.59 - 0.66)</td>
<td>0.88 (0.83 - 0.90)</td>
<td>**</td>
</tr>
<tr>
<td>09. T2DM History: Yes</td>
<td>Q2 (12 - 14)</td>
<td>0.87 (0.83 - 0.91)</td>
<td>0.91 (0.87 - 0.94)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.75 (0.71 - 0.79)</td>
<td>0.88 (0.82 - 0.90)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.66 (0.64 - 0.72)</td>
<td>0.94 (0.81 - 0.88)</td>
<td>**</td>
</tr>
<tr>
<td>10. MACE History: No</td>
<td>Q2 (12 - 14)</td>
<td>0.69 (0.66 - 0.73)</td>
<td>0.81 (0.79 - 0.84)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.63 (0.59 - 0.67)</td>
<td>0.87 (0.84 - 0.89)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.64 (0.61 - 0.68)</td>
<td>0.85 (0.83 - 0.89)</td>
<td>**</td>
</tr>
<tr>
<td>10. MACE History: Yes</td>
<td>Q2 (12 - 14)</td>
<td>0.88 (0.85 - 0.92)</td>
<td>0.91 (0.89 - 0.94)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.72 (0.68 - 0.75)</td>
<td>0.88 (0.83 - 0.89)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.67 (0.64 - 0.71)</td>
<td>0.85 (0.82 - 0.87)</td>
<td>**</td>
</tr>
<tr>
<td>11. Hypersomnia: No</td>
<td>Q2 (12 - 14)</td>
<td>0.80 (0.77 - 0.83)</td>
<td>0.91 (0.89 - 0.93)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.68 (0.65 - 0.70)</td>
<td>0.80 (0.84 - 0.89)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.65 (0.63 - 0.68)</td>
<td>0.85 (0.82 - 0.87)</td>
<td>**</td>
</tr>
<tr>
<td>11. Hypersomnia: Yes</td>
<td>Q2 (12 - 14)</td>
<td>1.14 (0.76 - 1.71)</td>
<td>1.80 (1.30 - 2.49)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>1.02 (0.66 - 1.57)</td>
<td>1.24 (0.82 - 1.80)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.65 (0.40 - 1.04)</td>
<td>1.61 (1.11 - 2.32)</td>
<td>****</td>
</tr>
<tr>
<td>12. Insomnia: No</td>
<td>Q2 (12 - 14)</td>
<td>0.81 (0.79 - 0.84)</td>
<td>0.92 (0.90 - 0.94)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.69 (0.66 - 0.71)</td>
<td>0.86 (0.84 - 0.89)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.67 (0.64 - 0.69)</td>
<td>0.84 (0.82 - 0.87)</td>
<td>**</td>
</tr>
<tr>
<td>12. Insomnia: Yes</td>
<td>Q2 (12 - 14)</td>
<td>0.69 (0.61 - 0.79)</td>
<td>0.86 (0.78 - 0.95)</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Q3 (15 - 16)</td>
<td>0.54 (0.46 - 0.63)</td>
<td>0.97 (0.86 - 1.10)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Q4 (&gt; 18)</td>
<td>0.46 (0.39 - 0.54)</td>
<td>0.98 (0.87 - 1.11)</td>
<td>****</td>
</tr>
</tbody>
</table>